Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) The stock’s Relative Strength Index (RSI) is 61.78, with weekly volatility at 7.11% and ATR at 2.43. The ARQT stock’s 52-week price range has touched low of $17.10 and a $40.88 high. Its shares traded lower over the last trading session, losing -3.68% on 02/11/21. The shares fell to a low of $34.00 before closing at $34.81. Intraday shares traded counted 0.16 million, which was 37.28% higher than its 30-day average trading volume of 261.67K. ARQT’s previous close was $36.14 while the outstanding shares total 37.75M.
Investors have identified the Biotechnology company Arcutis Biotherapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.51 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Arcutis Biotherapeutics Inc. (ARQT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 194.12 million total, with 21.15 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -3.76 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ARQT sounds very interesting.
Is the stock of ARQT attractive?
In related news, President and CEO, Watanabe Todd Franklin sold 10,000 shares of the company’s stock in a transaction that recorded on Feb 05. The sale was performed at an average price of 34.29, for a total value of 342,916. As the sale deal closes, the Director, Welgus Howard G. now sold 2,200 shares of the company’s stock, valued at 75,572. Also, Chief Financial Officer, Smither John W sold 3,750 shares of the company’s stock in a deal that was recorded on Feb 01. The shares were price at an average price of 35.00 per share, with a total market value of 131,250. Following this completion of acquisition, the Chief Financial Officer, Smither John W now holds 1,250 shares of the company’s stock, valued at 43,750. In the last 6 months, insiders have changed their ownership in shares of company stock by 4.50%.
6 out of 6 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Arcutis Biotherapeutics Inc.. 0 analysts has assigned a Sell rating on the ARQT stock. The 12-month mean consensus price target for the company’s shares has been set at $57.33.